Sanofi’s Sarclisa Gets EMA Backing In Myeloma, Mirroring FDA OK
But Experts Doubt It Can Overtake J&J’s Entrenched Darzalex
Executive Summary
The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.
You may also be interested in...
FDA Sarclisa Approval Marks Sanofi's Reentry Into Oncology
The anti-CD38 antibody will face an entrenched rival, J&J's Darzalex, for multiple myeloma.
Kancera Targets COVID-19 With Fractalkine Inhibitor
Sweden-based Kancera hopes to advance its investigative anti-inflammation drug in a Phase II trial to treat severe COVID-19 patients and then build its applications from there.
‘Follow The Money’: Sweden’s Calliditas Plans US Listing
Sweden’s Calliditas plans a US IPO to better position itself ahead of this year’s pivotal readout of its orphan drug Nefecon in inflammatory renal disease IgA nephropathy.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports